The evaluation of malignant astrocytoma score (MAS)
2013
Background/Aim. At the moment there are few scoring systems for malignant
astrocytoma but they are not widely accepted. The aim of this study was to
evaluate malignant astrocytoma score (MAS) on a new group of patients with
malignant astrocytoma, to compare MAS with other prognostic tools and to
describe the use of MAS in everyday practice in neurooncology. Methods. The
study was performed on 124 patients with supratentorial malignant
astrocytoma grade III or IV. They were operated on and subsequently
irradiated with 50-60 Gy. Results. The mean age of the patients was 57.3
years. The mean Karnofski performance status (KPS) of the functional
inpairment was 54. The removal of the tumor > 90% was done in 59.7% of
patients. The mean survival was 9.1 months, and 27.4% of patients had a
12-month survival. The area under receiver operating characteristic (ROC)
curve (AUC) of the MAS for predicting 6-, 12- and 18-month survival was
0.754, 0.783 and 0.882, respectively. We compared the MAS with the two
mostly cited scoring systems. The AUC for the same prediction for medical
research council (MRC) was 0.601, 0.693, 0.772 respectively. For the
Radiation Therapy Oncology Group (RTOG) the AUC was 0.732, 0.765, 0.827,
respectively. Conclusion. MAS represents a useful scoring system for
determining illness severity and prognosis in patients with malignant
supratentorial astrocytoma. It can be helpful in comparing single patients
or groups of patients, as well as results of different treatments and in
controlling the quality of hospital treatment and so on.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
26
References
0
Citations
NaN
KQI